Navigation Links
Teva and Barr Provide Update on Acquisition
Date:10/27/2008

t of Teva's and Barr's business, and the contingencies and uncertainties to which Teva and Barr may be subject, as well as other statements including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may" and other similar expressions, are "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Such statements are made based upon management's current expectations and beliefs concerning future events and their potential effects on Teva and on Barr.

Actual results may differ materially from the results anticipated in these forward-looking statements. Important factors that could cause or contribute to such differences include whether and when the proposed acquisition will be consummated and the terms of any conditions imposed in connection with such closing, Teva's ability to rapidly integrate Barr's operations and achieve expected synergies, diversion of management time on merger-related issues, Teva and Barr's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R), Neurontin(R), Lotrel(R), Famvir(R) and Protonix(R), Teva's and Barr's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva or Barr may obtain U.S. market exclusivity for certain of their new generic products and regulatory changes that may prevent Teva or Barr from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical i
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
2. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
3. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
4. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
5. Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System
6. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
7. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
8. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
9. The Plasmodium vivax genome provides new routes and challenges in the global fight against malaria
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... The Academy of Model Aeronautics is pleased ... Indiana Gov. Mike Pence, has declared August 15, 2015, ... a Family Fest and aviation themed Motorcycle Rally in ... Wounded Warrior Project. , National Model Aviation Day has ... foremost organization for model aviation—to celebrate the history of ...
(Date:5/5/2015)... May 05, 2015 A comment period ... wide range of key photonics technologies – regulations that ... of U.S. industry. To help the community understand and ... May on the proposed changes to U.S. Munitions ... by International Traffic in Arms Regulations (ITAR). , For ...
(Date:5/5/2015)... , May 5, 2015  Orexigen Therapeutics, Inc. (Nasdaq: ... first quarter 2015 on Friday, May 8 before the ... live webcast and conference call at 8:30 a.m. Eastern ... call may be accessed by phone by calling (800) ... The webcast can be accessed live on the Investors ...
(Date:5/5/2015)... Synedgen Inc. is pleased to announce ... Manager. , Dr. Nguyen brings to Synedgen critical regulatory ... company as it moves forward in the FDA regulatory ... two years. Dr. Nguyen will lead the management of ... documents that must be completed in order to initiate ...
Breaking Biology Technology:State of Indiana proclaims August 15 as Model Aviation Day 2Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2
... 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... interim results from a U.K. Phase Ia/Ib ... with advanced or,metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in ...
... Limited (NasdaqCM: PRAN) (ASX: PBT.AX), a biopharmaceutical,company ... treatments for,neurodegenerative disorders, today announced it has ... statements for the year ended,June 30, 2007, ... The annual,report its available on Prana,s website ...
... VaxGen,Inc. (Pink Sheets: VXGN) announced today that ... Directors as a result of accepting the CEO,position ... that Mr.,Anthony relinquish all corporate directorships in accepting ... (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) "On behalf of ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 4Jack Anthony to Resign From VaxGen's Board After Accepting CEO Position at Osprey Pharmaceuticals 2
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... tissue-engineered trachea (windpipe), utilising the patient,s own stem ... woman with a failing airway. The bioengineered trachea ... airway, thereby saving her life. These ... stem cells, combined with biologically compatible materials, can ...
... breakthrough against cancer, infectious diseases, or metabolic conditions like ... drugs, and even if they do clinical development usually ... medical research is conducted in highly fragmented groups focusing ... turn out not to work properly or to have ...
... created by a University of Central Florida professor show ... Professor James Turkson,s compounds disrupt the formation and spread ... The compounds, S3I-201 and S3I-M2001, break up a cancer-causing ... side effects so far. "The compounds are very ...
Cached Biology News:Adult stem cell breakthrough 2Adult stem cell breakthrough 3Systems biology brings hope of speeding up drug development 2Systems biology brings hope of speeding up drug development 3Two new compounds show promise for eliminating breast cancer tumors 2
... slides were designed to study protein expression patterns ... Tissue slices from three different species are ... be treated as a single histological slide for ... hybridization. This format allows a rapid analysis ...
... MacMelt software is used on ... melting profile of any DNA sequence ... in optimizing placement of primers and ... denaturing gradient gel electrophoresis (DGGE), constant ...
... Accurate To score SNPs, Polymorphic uses ... gold standard in DNA analysis. We use ... locus can be confirmed by sequencing in ... also provides sequence context information, further confirming ...
... Sub-Cell Model 192 and PowerPac basic power supply ... nucleic acids in agarose gels. This Model 192 ... 15 cm UV-transparent gel tray with fluorescent ruler, ... supply, 100-120 and 220-240 V, provides output of ...
Biology Products: